Previous close | 1.7000 |
Open | 1.7000 |
Bid | 1.6000 |
Ask | 2.1000 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 1.7000 - 1.7000 |
Contract range | N/A |
Volume | |
Open interest | 59 |
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended March 31, 2024, on Tuesday, May 14, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30
We feel now is a pretty good time to analyse Cellectar Biosciences, Inc.'s ( NASDAQ:CLRB ) business as it appears the...